People

James J. Dignam, PhD

Dr. Dignam's primary research involves the design, conduct, and analysis of cancer clinical trials, including early development (phase I), pilot efficacy and safety (phase II), and definitive evaluation (phase III) trials. He is the Executive Director of the Statistics and Data Management Center for NRG Oncology, a National Cancer Institute sponsored multi-center clinical trials group with over 500 recruitment sites in North America and beyond and over 100 active clinical trials. Dr. Dignam's methodology interests include trial monitoring and early stopping rules, competing risks, hazard function estimation, and prognostic modeling. He also has engaged in and led investigations into sociodemographic factors such as race/ethnicity and BMI/obesity on cancer prognosis and treatment response. Courses taught include introductory biostatistics, clinical trials, survival analysis, and regression modeling methods.

University of Pittsburgh, Graduate School of Public Health
Pittsburgh
PhD - Biostatistics
1994

Saint Xavier College
Chicago
BA - Mathematics
1986

Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.
Griggs JJ, Bohlke K, Balaban EP, Dignam JJ, Hall ET, Harvey RD, Hecht DP, Klute KA, Morrison VA, Pini TM, Rosner GL, Runowicz CD, Shayne M, Sparreboom A, Turner S, Zarwan C, Lyman GH. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2021 Jun 20; 39(18):2037-2048.
PMID: 33939491

Disparities in Breast Cancer: Narrowing the Gap.
Dignam JJ. Disparities in Breast Cancer: Narrowing the Gap. J Natl Cancer Inst. 2021 04 06; 113(4):349-350.
PMID: 32986842

Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, Davicioni E, Nguyen PL, Pollack A, Efstathiou JA, Dicker AP, Todorovic T, Margrave J, Liu YS, Dabbas B, Thompson DJS, Das R, Dignam JJ, Sweeney C, Attard G, Bahary JP, Lukka HR, Hall WA, Pisansky TM, Shah AB, Pugh SL, Shipley WU, Tran PT. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021 04 01; 7(4):544-552.
PMID: 33570548

Statistical Considerations in the Evaluation of Continuous Biomarkers.
Polley MC, Dignam JJ. Statistical Considerations in the Evaluation of Continuous Biomarkers. J Nucl Med. 2021 05 10; 62(5):605-611.
PMID: 33579807

Multicenter Clinical Cancer Research After COVID-19: A Perspective From NRG Oncology.
Gensheimer MF, Yom SS, Soto N, Dignam JJ, Le QT, Machtay M, Curran WJ. Multicenter Clinical Cancer Research After COVID-19: A Perspective From NRG Oncology. Int J Radiat Oncol Biol Phys. 2020 10 01; 108(2):483-485.
PMID: 32890539

Disparities in Breast Cancer: Narrowing the Gap.
Dignam JJ. Disparities in Breast Cancer: Narrowing the Gap. J Natl Cancer Inst. 2020 Sep 28.
PMID: 32986842

Do reminder emails and past due notifications improve patient completion and institutional data submission for patient-reported outcome measures?
Pugh SL, Rodgers JP, Moughan J, Bonanni R, Boparai J, Chen RC, Dignam JJ, Bruner DW. Do reminder emails and past due notifications improve patient completion and institutional data submission for patient-reported outcome measures? Qual Life Res. 2021 Jan; 30(1):81-89.
PMID: 32894431

Predictors of pressure injury development in critically ill adults: A retrospective cohort study.
Sala JJ, Mayampurath A, Solmos S, Vonderheid SC, Banas M, D'Souza A, LaFond C. Predictors of pressure injury development in critically ill adults: A retrospective cohort study. Intensive Crit Care Nurs. 2021 Feb; 62:102924.
PMID: 11773293

Characteristics of Participation in Patient-Reported Outcomes and Electronic Data Capture Components of NRG Oncology Clinical Trials.
Pugh SL, Rodgers JP, Yeager KA, Chen RC, Movsas B, Bonanni R, Dignam J, Bruner DW. Characteristics of Participation in Patient-Reported Outcomes and Electronic Data Capture Components of NRG Oncology Clinical Trials. Int J Radiat Oncol Biol Phys. 2020 11 15; 108(4):950-959.
PMID: 32590048

Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Berry D, Clarke N, Collette L, D'Amico A, Lourenco RA, Dignam J, Eisenberger M, James N, Fizazi K, Gillessen S, Loriot Y, Mottet N, Parulekar W, Sandler H, Spratt DE, Sydes MR, Tombal B, Williams S, Sweeney CJ. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. J Clin Oncol. 2020 09 10; 38(26):3032-3041.
PMID: 32552276

View All Publications

Co-recipient, Statistical Partnership Among Academe, Industry, and Government (SPAIG) Award
American Statistical Association
2021

Elected Fellow
Society for Clinical Trials
2019

Inducted Member
Delta Omega, National Public Health Honor Society
1991